Your browser doesn't support javascript.
loading
Human trials exploring anti-aging medicines.
Guarente, Leonard; Sinclair, David A; Kroemer, Guido.
Afiliación
  • Guarente L; Department of Biology, Massachusetts Institute for Technology, Cambridge, MA 02139; Academy for Healthspan and Lifespan Research (AHLR), New York, NY, USA. Electronic address: leng@mit.edu.
  • Sinclair DA; Academy for Healthspan and Lifespan Research (AHLR), New York, NY, USA; Blavatnik Institute, Genetics Department, Harvard Medical School, Boston, MA 02115, USA.
  • Kroemer G; Academy for Healthspan and Lifespan Research (AHLR), New York, NY, USA; Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France; Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France; Institut du Cancer Paris CARPEM, Department of Biology, Hôpital Européen Georges Pompidou, AP-HP, Paris, France. Electronic address: kroemer@orange.fr.
Cell Metab ; 36(2): 354-376, 2024 02 06.
Article en En | MEDLINE | ID: mdl-38181790
ABSTRACT
Here, we summarize the current knowledge on eight promising drugs and natural compounds that have been tested in the clinic metformin, NAD+ precursors, glucagon-like peptide-1 receptor agonists, TORC1 inhibitors, spermidine, senolytics, probiotics, and anti-inflammatories. Multiple clinical trials have commenced to evaluate the efficacy of such agents against age-associated diseases including diabetes, cardiovascular disease, cancer, and neurodegenerative diseases. There are reasonable expectations that drugs able to decelerate or reverse aging processes will also exert broad disease-preventing or -attenuating effects. Hence, the outcome of past, ongoing, and future disease-specific trials may pave the way to the development of new anti-aging medicines. Drugs approved for specific disease indications may subsequently be repurposed for the treatment of organism-wide aging consequences.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Metformina / Neoplasias Idioma: En Revista: Cell Metab Asunto de la revista: METABOLISMO Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Metformina / Neoplasias Idioma: En Revista: Cell Metab Asunto de la revista: METABOLISMO Año: 2024 Tipo del documento: Article